COVID-19 vaccines and thrombosis with thrombocytopenia syndrome

  title={COVID-19 vaccines and thrombosis with thrombocytopenia syndrome},
  author={Chih-Cheng Lai and Wen-Chien Ko and Chih-Jung Chen and Po‐Yen Chen and Yhu-Chering Huang and P.-I. Lee and Po-Ren Hsueh},
  journal={Expert Review of Vaccines},
  pages={1027 - 1035}
ABSTRACT Introduction To combat COVID-19, scientists all over the world have expedited the process of vaccine development. Although interim analyses of clinical trials have demonstrated the efficacy and safety of COVID-19 vaccines, a serious but rare adverse event, thrombosis with thrombocytopenia syndrome (TTS), has been reported following COVID-19 vaccination. Areas covered This review, using data from both peer-reviewed and non-peer-reviewed studies, aimed to provide updated information… 

COVID-19 and Blood Clots: Is it only The Virus to be Blamed? What are new Updates? A Systematic Review

  • M. Mahmood
  • Medicine
    Journal of Cardiology and Cardiovascular Research
  • 2022
SARS-CoV-2 may cause blood clots, but it is not the only reason, and some medicines used to treat patients, and COVID-19 vaccines are added to the list of causes ofBlood clots despite the rare incidence of blood clOTS recorded in vaccinated people.

A review of the safety and efficacy of current COVID-19 vaccines

This study reviewed the efficacy/effectiveness, immunogenicity, and safety profile of the 12 most progressed COVID-19 vaccines and discussed the challenges and prospects of the vaccine-based approaches in a global crisis.

COVID-19 and cardiovascular disease: manifestations, pathophysiology, vaccination, and long-term implication

Cardiovascular involvement in the COVID-19 pandemic is reviewed with respect to clinical features, pathogenesis, long-term effects, and the adverse effects of treatments and vaccines based on the latest evidence.

Case Report: A Case of COVID Vaccine-Induced Thrombotic Thrombocytopenia Manifested as Pulmonary Embolism and Hemorrhagia. A First Reported Case From Slovakia

A case of a young male patient who developed severe thrombocytopenia and pulmonary embolism 12 days after the first dose of the CoVID-19 vaccine is presented, the first known case of VITT in Slovakia.

The Population-Wide Risk-Benefit Profile of Extending the Primary COVID-19 Vaccine Course Compared with an mRNA Booster Dose Program

It is demonstrated that the rate of vaccine efficacy waning has a significant impact on COVID-19 hospitalisations with the greatest effect in populations with lower vaccination coverage, and there was greater benefit associated with a booster vaccination strategy compared to targeting the unvaccinated population, once >50% of the population had received their primary vaccination course.

Potential Anionic Substances Binding to Platelet Factor 4 in Vaccine-Induced Thrombotic Thrombocytopenia of ChAdOx1-S Vaccine for SARS-CoV-2

Five potential anionic substances of the ChAdOx1-S vaccine that can combine with PF4 and trigger VITT are proposed, including the proteins on the surface of adenovirus and the negatively charged impurity proteins expressed by the vaccine.

SARS-CoV-2-induced Host Metabolic Reprogram (HMR): Nutritional Interventions for Global Management of COVID-19 and Post-Acute Sequelae of COVID-19 (PASC)

The ongoing epidemic of the residual, non-viral host metabolic disorders and complications in COVID-19 survivors is explained and the supportive role of specific host system-targeted nutritional interventions to manage PASC, the newly emerged post-COVID metabolic syndrome is attempted.

Vaccination and Mortality of Patients with a Novel Coronavirus Infection (COVID-19): A Global Approach

An increase in VR correlates with a decrease in MpCOV, which was higher in countries where VR were lower when groups of countries with VR of 20–39 %, 40–59 %, 60–79 %, and ≥80 % were compared.

A randomized controlled trial of heterologous ChAdOx1 nCoV-19 and recombinant subunit vaccine MVC-COV1901 against COVID-19

The findings support the use of heterologous prime-boost with ChAdOx1 and protein-based subunit vaccines, and both spike-specific antibody-secreting B and T cell responses were substantially enhanced by theheterologous schedule.

COVID-19: State of the Vaccination

Six vaccines, including two using novel mRNA technology, are EU-listed by the World Health Organisation, and promising published trial data are available for nine more, and efficacy is good, there are various barriers to their global use.



Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination

It is recommended that treatment with platelet transfusions be avoided because of the risk of progression in thrombotic symptoms and that the administration of a nonheparin anticoagulant agent and intravenous immune globulin be considered for the first occurrence of these symptoms.

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

Vaccination with Ch adenoviral vector encoding the spike protein antigen of severe acute respiratory syndrome coronavirus 2 can result in the rare development of immuneThrombotic thrombocytopenia mediated by platelet-activating antibodies against PF4, which clinically mimics autoimmune heparin-induced thromBocy topenia.

Thrombocytopenia and Intracranial Venous Sinus Thrombosis after “COVID-19 Vaccine AstraZeneca” Exposure

Early observations insinuate that the exposure to the “COVID-19 vaccine AstraZeneca” might trigger the expression of antiplatelet antibodies, resulting in a condition with thrombocytopenia and venous thromBotic events, and patients’ treatment should address the thrombo-embolic manifestations, the coagulation disorder, and the underlying immunological phenomena.

Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH.

Based on reports of atypically located thromboses following vaccination with the AstraZeneca COVID-19 vaccine, the Society of Thrombosis and Haemostasis Research has issued guidance statements on the recognition, diagnosis, and treatment of this rare complication.

Treatment options for COVID-19: The reality and challenges

A Review of Treatment of Coronavirus Disease 2019 (COVID-19): Therapeutic Repurposing and Unmet Clinical Needs

Traditional Chinese medicine with antiviral effects on SARS-CoV-2 and immune-modulation is widely used for COVID-19 patients in China, and is worthy of further studies.

Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination

Findings in five patients who presented with venous thrombosis andThrombocytopenia 7 to 10 days after receiving the first dose of the ChAdOx1 nCoV-19 adenoviral vector vaccine against coronavirus disease 2019 (Covid-19) suggest that they represent a rare vaccine-related variant of spontaneous heparin-induced thromBocytopensia.

Deep vein thrombosis (DVT) occurring shortly after the second dose of mRNA SARS-CoV-2 vaccine

This is the first reported case of DVT presenting as an adverse event post-SARS-CoV-2 vaccination, and the intense immunological response evoked by the second dose of vaccine could be a trigger for the thrombotic event described.

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older and safety over a median of 2 months was similar to that of other viral vaccines.